Viral delivery for gene therapy against cell movement in cancer.
Viral delivery for gene therapy against cell movement in cancer.
复制标题
DOI：
10.1016/j.addr.2011.05.005
复制
发表时间：
2011-07
影响因子：
16.1
通讯作者：
Te-Lang Wu;Dongming Zhou
中科院分区：
文献类型：
--
作者：
Te-Lang Wu;Dongming Zhou
病毒传递癌症基因治疗是一种很有前途的方法，传统的放疗或化疗来限制癌细胞的增殖和运动已经遇到了阻力。基于对病毒载体生物学的新认识，用于癌症基因治疗的治疗性病毒载体得到了改进，安全性和有效性更高，并从非复制向复制能力转变。传统的溶瘤载体专注于消除肿瘤生长，而新型载体同时靶向癌细胞的上皮-间质转化（epithelial-to-mesenchymal transition， EMT），可以进一步预防和逆转肿瘤的侵袭性进展。在这篇综述中，我们重点介绍了癌症基因治疗的临床试验和临床前数据，并提出了进一步提高溶瘤病毒载体在癌症基因治疗中的安全性和有效性的方法。
Viral delivery for cancer gene therapy is a promising approach, where traditional radiotherapy or chemotherapy to limit proliferation and movement of cancer cells has met resistance. Based on the new understanding of the biology of the viral vectors, therapeutic viral vectors for cancer gene therapy have been improved for greater safety and efficacy as well as transitioned from being non-replicating to replication-competent. Traditional oncolytic vectors have focused on eliminating tumor growth, while novel vectors simultaneously target epithelial-to-mesenchymal transition (EMT) in cancer cells, which could further prevent and reverse the aggressive tumor progression. In this review, we highlight the illustrative examples of cancer gene therapy in clinical trials as well as preclinical data and include proposals on methods to further enhance the safety and efficacy of oncolytic viral vectors in cancer gene therapy.